Will weight loss drugs eat into supermarkets’ profits?

view from shopping trolley: PSA story
The skyrocketing demand for weight loss medications like Ozempic could temper shoppers’ appetites at our major supermarkets, Morgan Stanley says The Danish maker of GLP-1 receptor antagonists Ozempic and Wegovy, Novo Nordisk, reported sales of more than US$33.7bn in 2023, with forecasts suggesting continued, strong growth. In a note to investors, Morgan Stanley indicated the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Skill and judgement needed on opium
Next An upgrade for TWC loyalty scheme